Poor
Mostly Unaligned
Patient Risk:
Low
Summary
Only one claim is even partially aligned with the provided label excerpt (indication related to elevated triglycerides). All other claims concern pricing, discounts/coupons, patient assistance, and patent/generic timing, none of which are supported by the supplied FDA label section.
Category Scores
Accurate Statements
Vascepa is indicated for reducing triglycerides in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
1 INDICATIONS AND USAGE
Vascepa is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) with established cardiovascular disease or diabetes mellitus plus additional risk factors.
1 INDICATIONS AND USAGE
Unsupported Statements
Vascepa (icosapent ethyl) is an omega-3 fatty acid medication primarily used to treat high triglycerides.
Partially supported only in terms of triglyceride-related indications; the provided label excerpt does not explicitly support the characterization as an 'omega-3 fatty acid medication' or that it is 'primarily used' for high triglycerides.
As of 2023, the cost of Vascepa without insurance can range from around $100 to $200 per month.
No pricing/cost information in the provided label excerpt.
The cost of Vascepa without insurance depends on dosage and quantity.
No pricing rationale or dosage/quantity linkage in the provided label excerpt.
Some manufacturers and pharmaceutical companies offer discount programs or coupons for Vascepa.
No discount/coupon program information in the provided label excerpt.
Discount programs or coupons are subject to specific terms, eligibility criteria, and availability.
No discount/coupon terms, eligibility, or availability information in the provided label excerpt.
Some pharmaceutical companies offer patient assistance programs that can help make Vascepa more affordable.
No patient assistance program information in the provided label excerpt.
Amarin, the manufacturer of Vascepa, may have patient assistance programs in place.
The provided label excerpt does not mention Amarin or any patient assistance programs.
As generic or biosimilar versions of Vascepa become available, prices may decrease.
No generic/biosimilar or pricing-impact information in the provided label excerpt.
Prices of Vascepa can vary among different retailers, including pharmacies, wholesalers, and online pharmacies.
No retailer pricing information in the provided label excerpt.
The patent for Vascepa currently holds exclusivity rights until June 2028.
No patent/exclusivity information in the provided label excerpt.
Generic or biosimilar versions of Vascepa may become available earlier than June 2028, potentially affecting pricing and accessibility.
No generic/biosimilar availability timing or accessibility/pricing effect information in the provided label excerpt.
Contradictions
Important Omissions
No label-supported dosing, administration, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, or storage/handling information was evaluated because only '1 INDICATIONS AND USAGE' was provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about cost/access and exclusivity rather than clinical safety. The only clinical claim is generally consistent with triglyceride-related indications, but its phrasing ('omega-3' and 'primarily used') is not explicitly supported by the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Most extracted claims (pricing, discounts/coupons, patient assistance, and patent/generic timing) are not supported by the supplied FDA label excerpt.
Suggested Improvement
Restrict claims to FDA-label-supported information from the available excerpt (indications/limitations of use). Remove or clearly qualify all pricing, discount/patient assistance, and patent/generic timing statements unless supported by additional label sections provided by the user.